List view / Grid view
29 September 2014 | By Roche
Roche announced positive data from the coBRIM Phase III study...
29 September 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab)...
26 September 2014 | By Vela Diagnostics
Vela Diagnostics announced the CE-IVD launch of the Sentosa® SQ Melanoma Panel for Next-Generation Sequencing (NGS)- based gene sequence variant detection and identification...
26 September 2014 | By Roche
Roche announced the launch of a new Global Access Program for HIV viral load testing...
26 September 2014 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States regulatory approval from all government authorities required by the agreement and other closing conditions...
26 September 2014 | By Almirall S.A
Almirall S.A. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the regulatory approval of Duaklir® Genuair® (aclidinium bromide/formoterol fumarate) in all EU member states...
26 September 2014 | By Novo Nordisk
Novo Nordisk announced that the company will establish a new obesity research unit in Seattle, Washington, in the US...
26 September 2014 | By AbbVie
AbbVie announced that the U.S. Food and Drug Administration has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough...
25 September 2014 | By kdm communications
Microfluidics specialist Dolomite has teamed up with Lab on a Chip and the Chemical and Biological Microsystems Society to create the first ever MicroTAS Video Competition...
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
25 September 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015 and will become Deputy Chairman with effect from 1 April 2015...
25 September 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK...
25 September 2014 | By Helsinn
Helsinn Group announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress...
25 September 2014 | By Photocure ASA
Cysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond that achieved with current standard of care...
24 September 2014 | By Sigma-Aldrich
Sigma-Aldrich Corporation’s SAFC® Commercial custom manufacturing services business unit, and Baxter’s BioPharma Solutions business have established a collaborative manufacturing agreement...
